Hybrid molecules inhibiting myeloperoxidase activity and serotonin reuptake: A possible new approach of major depressive disorders with inflammatory syndrome

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 8, 2014, Pages 1122-1132

  Soubhye, Jalal ^a   Aldib, Iyas ^a   Prévost, Martine ^a   Elfving, Betina ^b   Gelbcke, Michel ^a   Podrecca, Manuel ^c   Conotte, Raphaël ^c   Colet, Jean Marie ^c   Furtmüller, Paul G ^d   Delporte, Cédric ^a   Rousseau, Alexandre ^a   Vanhaeverbeek, Michel ^a   Nève, Jean ^a   Obinger, Christian ^d   Zouaoui Boudjeltia, Karim ^a   Van Antwerpen, Pierre ^a   Dufrasne, François ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF MONS   (Belgium)

^d Vienna Institute of Technology   (Austria)

Author keywords

atherosclerosis; depression; irreversible inhibitor; myeloperoxidase; serotonin

Indexed keywords

3 (AMINOALKYL) 5 FLUOROINDOLE DERIVATIVE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MYELOPEROXIDASE; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; 5-FLUOROINDOLE; ANTIDEPRESSANT AGENT; INDOLE DERIVATIVE; PEROXIDASE; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INACTIVATION; INFLAMMATION; LOW DRUG DOSE; MAJOR DEPRESSION; MALE; MOLECULAR DOCKING; NONHUMAN; RAT; STRUCTURE ANALYSIS; TOXICITY TESTING; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; CELL LINE; DEPRESSIVE DISORDER, MAJOR; HEK293 CELL LINE; HUMAN; METABOLISM;

ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR DISEASES; CELL LINE; DEPRESSIVE DISORDER, MAJOR; HEK293 CELLS; HUMANS; INDOLES; INFLAMMATION; PEROXIDASE; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 84904246317     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12236     Document Type: Article

References (55)

1. Libby P, etal. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-325.
2. Holtzheimer PE, Mayberg HS,. Stuck in a rut: rethinking depression and its treatment. Trends Neurosci 2011; 34: 1-9.
3. Lee S, etal. Depression research: where are we now? Mol Brain 2010; 3: 8.
4. Sluzewska A, etal. Indicators of immune activation in major depression. Psychiatry Res 1996; 64: 161-167.
5. Maes M, etal. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9: 853-858.
6. Maes M, etal. Immune disturbances in treatment-resistant depression: modulation by antidepressive treatments. Hum Psychopharmacol Clin Exp 1997; 12: 153-162.
7. Vaccarino V, etal. Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biol Psychiatry 2008; 64: 476-483.
8. Klebanoff SJ,. Myeloperoxidase: friend and foe. J Leukoc Biol 2005; 77: 598-625.
9. Maes M, etal. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J Affect Disord 2010; 125: 287-294.
10. Nicholls SJ, Hazen SL,. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 1102-1111.
11. Wozniak G, etal. Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis. Med Sci Monit 2011; 17: RA205-RA214.
12. Uno K, Nicholls SJ,. Biomarkers of inflammation and oxidative stress in atherosclerosis. Biomark Med 2010; 4: 361-373.
13. Huo Y, Ley FK,. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 2004; 14: 18-22.
14. Angiolillo DJ, etal. Basic principles of platelet biology and clinical implications. Circ J 2010; 74: 597-607.
15. Tseng Y-L, etal. A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. Thromb Res 2010; 126: 517-523.
16. Bampalis VG, etal. Fluoxetine inhibition of 5-HT-potentiated platelet aggregation in whole blood. Thromb Haemost 2010; 104: 1272-1274.
17. Galan AM, etal. Platelets and blood cells. Thromb Haemost 2009; 102: 511-519.
18. Atar D, etal. Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study. Neuropsychopharmacology 2007; 32: 2369-2374.
19. Serebruany VL, etal. Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail 2003; 5: 517-521.
20. Novio S, etal. Effects of fluoxetine on the oxidative status of peripheral blood leucocytes of restraint-stressed mice. Basic Clin Pharmacol Toxicol 2011; 109: 365-371.
21. Eren I, etal. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem Res 2007; 32: 1188-1195.
22. Kumar A, Garg R,. Protective effects of antidepressants against chronic fatigue syndrome-induced behavioral changes and biochemical alterations. Fundam Clin Pharmacol 2009; 23: 89-95.
23. Chung YC, etal. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 2010; 185: 1230-1237.
24. Crino PB, etal. Neurotoxic effects of partially oxidized serotonin: tryptamine-4,5-dione. Brain Res 1989; 504: 247-257.
25. Ximenes VF, etal. Serotonin as a physiological substrate for myeloperoxidase and its superoxide-dependent oxidation to cytotoxic tryptamine-4,5-dione. Biochem J 2009; 425: 285-293.
26. Suchet K, etal. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003; 8: 365-370.
27. For reviews on the subject see:, Maia RDC, Fraga CAM,. Discovery of dual chemotherapy drug candidates designed by molecular hybridization. Curr Enzyme Inhib 2010; 6: 171-182
28. Meunier B,. Hybrid molecules with a dual mode of action: dream or reality? Acc Chem Res 2008; 41: 69-77
29. Richards J,. Patent issues relating to hybrid drugs. Expert Opin Ther Pat 2008; 18: 1191-1194.
30. Van der Steen JW,. Assessing overmedication: biology, philosophy and common sense. Acta Biotheor 2003; 51: 151-171.
31. Soubhye J, etal. Structure-based design, synthesis, and pharmacological evaluation of 3-(Aminoalkyl)-5-fluoroindoles as myeloperoxidase inhibitors. J Med Chem 2010; 53: 8747-8759.
32. Soubhye J, etal. Design, synthesis, and structure-activity relationship studies of novel 3-alkylindole derivatives as selective and highly potent myeloperoxidase inhibitors. J Med Chem 2013; 56: 3943-3958.
33. Schmitz WD, etal. Homotryptamines as potent and selective serotonin reuptake inhibitors (SSRIs). Bioorg Med Chem Lett 2005; 15: 1619-1621.
34. Mattson RJ, etal. Conformationally restricted homotryptamines. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors. J Med Chem 2005; 48: 6023-6034.
35. King HD, etal. Conformationally restricted homotryptamines. Part 7: 3-cis-(3-aminocyclopentyl)indoles as potent selective serotonin reuptake inhibitors. J Med Chem 2010; 53: 7564-7572.
36. Kristensen AS, etal. Mutational scanning of the human serotonin transporter reveals fast translocating serotonin transporter mutants. Eur J Neurosci 2004; 19: 1513-1523.
37. Larsen MB, etal. The chicken serotonin transporter discriminates between serotonin-selective reuptake inhibitors: a species-scanning mutagenesis study. J Biol Chem 2004; 279: 42147-42156.
38. Altschul SF, etal. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25: 3389-3402.
39. Eswar N, etal. Comparative protein structure modeling with MODELLER. In: Current Protocols in Bioinformatics. Hoboken, NJ: John Wiley & Sons Inc., 2006: 1-30. Supplement 15.
40. Pei J, Grishin N,. PROMALS: towards accurate multiple sequence alignments of distantly related proteins. Bioinformatics 2007; 23: 802-808.
41. Adkins EM, etal. Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition. Mol Pharmacol 2001; 59: 514-523.
42. Sherman W, etal. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 2006; 49: 534-553.
43. Wang H, etal. Structural basis for action by diverse antidepressants on biogenic amine transporters. Nature 2013; 503: 141-145.
44. Penmatsa A, etal. X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 2013; 503: 85-90.
45. Celik L, etal. Binding of serotonin to the human serotonin transporter. Molecular modeling and experimental validation. J Am Chem Soc 2008; 130: 3853-3865.
46. Jantschko W, etal. Exploitation of the unusual thermodynamic properties of human myeloperoxidase in inhibitor design. Biochem Pharmacol 2005; 69: 1149-1157.
47. Malle E, etal. Myeloperoxidase: a target for new drug development? Br J Pharmacol 2007; 152: 838-854.
48. Segura M, etal. Synthesis of the major metabolites of paroxetine. Bioorg Chem 2003; 31: 248-258.
49. Ward J, etal. Mechanistic characterization of a 2-thioxanthine myeloperoxidase inhibitor and selectivity assessment utilizing click chemistry-activity-based protein profiling. Biochemistry 2013; 52: 9187-9201.
50. Tiden AK, etal. 2-thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation. J Biol Chem 2011; 286: 37578-37589.
51. Kelvin AS, Håkansson S,. Comparative acute toxicity of paroxetine and other antidepressants. Acta Psychiatr Scand Suppl 1989; 80: 31-33.
52. Ryan PM, etal. The toxicity profile of a single dose of paroxetine: an alternative approach to acute toxicity testing in the rat. Pharmacol Toxicol 2001; 88: 59-66.
53. Franck T, etal. A new easy method for specific measurement of active myeloperoxidase in human biological fluids and tissue extracts. Talanta 2009; 80: 723-729.
54. Delporte C, etal. Simultaneous measurement of protein-bound 3-chlorotyrosine and homocitrulline by LC-MS/MS after hydrolysis assisted by microwave: application to the study of myeloperoxidase activity during hemodialysis. Talanta 2012; 99: 603-609.
55. Parry MF, etal. Myeloperoxidase deficiency: prevalence and clinical significance. Ann Intern Med 1981; 95: 293-301.